Could a natural sweetener from hydrangeas treat Alzheimer’s disease?

hydrangea Alzheimer's disease

Amyloid β (Aβ) aggregation is primarily responsible for the development of Alzheimer’s disease (AD). 

In a new mouse model study, South Korean researchers investigated the effect of phyllodulcin — a natural sweetener found in the hydrangea plant — in inhibiting Aβ accumulation. The results suggest that phyllodulcin effectively inhibits Aβ accumulation and decomposes the pre-aggregated Aβ, suggesting its beneficial role in treating Alzheimer’s disease. Going ahead, these results can provide important clues for the development of effective treatment for AD. 

Alzheimer’s disease is the most common neurodegenerative disorder in the world, associated with symptoms like memory loss and cognitive impairment. Brain lesions caused by the aggregation of amyloid β (Aβ) and neurofibrillary tangles are believed to be the main cause of AD. Therefore, therapeutic agents that control Aβ aggregation may be useful in delaying the onset and progression of AD.

While many drugs targeting Aβ have been developed, they have failed to demonstrate efficacy in clinical trial studies. Also, the use of approved antibody drugs is associated with high costs of treatment and uncertain efficacy. Therefore, developing a simple and efficient drug that targets Aβ for the treatment of AD is needed. 

One such therapeutic agent could be phyllodulcin, a natural sweetening agent found in Hydrangea macrophylla var. thunbergia. Previous studies have shown that phyllodulcin, a type of polyphenol, can efficiently penetrate the blood-brain barrier and be uniformly distributed in the brain. Recent research also suggests that polyphenols can inhibit Aβ aggregation. However, the role of phyllodulcin for the management of Alzheimer’s disease has not been studied.

To fill this knowledge gap, assistant professor Se Jin Jeon of the Department of Integrative Biotechnology, College of Science and Technology, Sahmyook University, along with a group of researchers from Korea, studied the effect of phyllodulcin on Aβ aggregation and various pathological features in an animal model of Alzheimer’s disease. Their study was published in the Biomedicine & Pharmacotherapy journal.

Jeon said: “We focused on increasing the level of evidence regarding phyllodulcin by using various experimental techniques. We hypothesized that phyllodulcin may enter the brain and inhibit Aβ aggregation, resulting in the improvement of various brain lesions appearing in AD. To examine our hypothesis, we investigated the effect of phyllodulcin on the Aβ aggregation and various pathological hallmarks in an animal model of AD.” 

Research details:phyllodulcin and Alzheimer’s disease

The researchers demonstrated that phyllodulcin could efficiently inhibit Aβ aggregation as well as decompose pre-aggregated Aβ clumps, both in in vivo (cells) and in vitro (animal model) experiments. A toxicity assay revealed that phyllodulcin prevents Aβ-induced neurotoxicity and attributed this to the reduced Aβ aggregates.

The study revealed that phyllodulcin reduced the memory impairments caused by the accumulation of amyloid proteins.

The hippocampus is the site for memory formation, which is inhibited by Aβ clumps in AD, leading to memory loss. The experiments revealed that phyllodulcin could counter this effect by reducing the deposition of Aβ in the hippocampus and increasing memory-related processes. Additionally, it also minimized neuroinflammation in the hippocampus and inhibited the activation of microglia and astrocytes (cells responsible for playing a key role in neuroinflammation in the pathology of AD). 

Jeon concluded: “Our study is the first to report that phyllodulcin can modify the underlying pathogenesis of Alzheimer’s disease, suggesting the possibility of preventing dementia or delaying the progression of the disease.

“It will take more than 20 years to develop a treatment, but at this stage, the results of this study can be used to provide a guide map that can help prevent or improve dementia symptoms.”

Partnering 2030: The Biotech Perspective 2023

Download Inpart’s latest report revealing the priorities of out-licensers worldwide.
Explore other topics: Alzheimer'sResearchSouth Korea

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.